Key facts
- It has raised $1.4M; the latest was Early Stage VC in Mar 2026.
- Notable investors include Leader Venture Capital, Dalton Venture, Holley Group, Bangming Capital, Christine International Holdings — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Bochuang Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Bochuang Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Bochuang Biotechnology
Manufacturer of biological tissues and derivative medical device products designed to serve alveolar bone, membrane, and diseased cornea repair needs in China. The company's products include a series of high-end artificial corneas, periosteum, dura mater, nerve sheath, and other innovative products, thereby providing patients with eye diseases with restorative therapies.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2022
- Website
- bioboch.com/
- Ownership
- Privately Held (backing)
Bochuang Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bochuang Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bochuang Biotechnology in its N-PORT filings yet. We sweep new filings monthly.